Kornimate/medical-research-clean huggingface dataset:
the effectiveness of a bladder training video for management of lower urinary tract symptoms.

Conditions: Nonneurogenic Lower Urinary Tract Dysfunction; Dysfunctional Elimination Syndrome

Summary: children with non-neurogenic lower urinary tract dysfunction (nlutd) represent a significant subgroup of pediatric urology patients, comprising up to 30 percent of some out-patient clinics. these children present with urinary tract infections (utis), abnormal voiding habits and various other lower urinary tract symptoms (luts) such as incontinence, urinary urgency and urinary frequency. furthermore, the effects of nlutd on a child's physical health, mental health and its potential negative clinical sequelae, which includes upper or lower urinary tract damage, must be taken into account when treating these children. these patients have complex needs requiring a significant amount of health teaching and it is imperative to determine the effectiveness of the various modes of delivering urotherapy. to determine the best modality to deliver urotherapy, this trial will compare the effectiveness of a 7 minute bladder training video to the effectiveness of standard urotherapy provided at a pediatric urology clinic at improving nlutd/des symptoms and quality of life in children between 5-10 years of age.


Eligibility criteria:
inclusion criteria: * children aged 6-10 years old * bladder dysfunction (diagnosis of nlutd or des) exclusion criteria: * grade 3 or 4 hydronephrosis * grade 3, 4 or 5 vesicoureteral reflux * other diagnoses which affect bladder bowel function (i.e. spina bifida) * english as a second language * diagnosed learning disability (i.e. add or adhd) * mental health condition (i.e. anxiety or depression) * received intensive urotherapy and biofeedback in past 12 months * child is diagnosed with primary nocturnal enuresis

Keywords: pediatric urology urotherapy nonneurogenic lower urinary tract dysfunction dysfunctional elimination syndrome randomized controlled trial
effects of food cooking on diabetes-2 risk factors

Conditions: Obesity; Type 2 Diabetes; Insulin Resistance; Cardiovascular Disease

Summary: the aim of the project is to investigate the effects of advanced glycation end products (ages) formed in food during the cooking process as well as ages formed naturally in the human body, on insulin sensitivity and risk factors for type 2 diabetes. the hypothesis is that i) food content of ages is lower using boiling and steaming cooking methods and that ii) ages formation in the body is lower at low dietary intake of certain sugar forms.


Eligibility criteria:
inclusion criteria: * women, healthy between 20 and 50 y * bmi between 25 and 40 kg/m2 * weight circumference over 88 cm exclusion criteria: * weigh changes within the last 2 months more than +/- 3 kg * physical activity more than 8 h per week * smoking * medications and supplements * being vegetarian or vegan * pregnancy or breast feeding * postmenopause * chronic disease * previous gastric bypass surgery * blood donation within the last 3 months * involvement in other clinical trials * allergic to paraaminobenzoic acid

Keywords: advanced glycation end products insulin sensitivity obesity inflammation metabolomics appetite cvd
temozolomide in treating patients with recurrent or progressive malignant glioma

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of temozolomide in treating patients who have recurrent or progressive malignant glioma.

objectives: * determine the progression-free survival and response rate of patients with recurrent or progressive malignant glioma treated with temozolomide. * determine whether certain categories of malignant gliomas, such as oligodendroglioma, are more sensitive to temozolomide. * determine the toxicity of this regimen in these patients. outline: patients are stratified according to histologic categories (recurrent glioblastoma multiforme \[closed to accrual 11/30/01\] vs recurrent anaplastic astrocytoma vs recurrent anaplastic oligodendroglioma). patients receive oral temozolomide twice daily for 5 consecutive days. courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 100 patients will be accrued for this study within 3 years.

Eligibility criteria:
disease characteristics: * histologically proven recurrent or progressive malignant glioma of one of the following types: * anaplastic oligodendroglioma or oligoastrocytoma * anaplastic astrocytoma * glioblastoma multiforme (stratum closed to accrual 11/30/01) * patients who have failed radiotherapy are eligible * measurable disease by ct scan or mri patient characteristics: age: * 18 and over performance status: * karnofsky 70-100% life expectancy: * at least 12 weeks hematopoietic: * absolute neutrophil count greater than 1,500/mm\^3 * platelet count greater than 100,000/mm\^3 * hemoglobin greater than 10 g/dl hepatic: * sgot or sgpt less than 3 times upper limit of normal (uln) * alkaline phosphatase less than 2 times uln (if greater than 2 times uln then a gamma glutamyl transferase test must be performed) renal: * bun less than 1.5 times uln * creatinine less than 1.5 times uln other: * not pregnant or nursing * negative pregnancy test * fertile patients must use effective barrier contraception * no other serious concurrent infection or other medical illness that would preclude study entry * no frequent vomiting or partial bowel obstruction * hiv negative * no aids-related illness * no other concurrent malignancy except carcinoma in situ of the cervix or basal cell skin cancer prior concurrent therapy: biologic therapy: * no concurrent epoetin alfa chemotherapy: * at least 6 weeks since other prior chemotherapy endocrine therapy: * not specified radiotherapy: * see disease characteristics * at least 3 months since prior radiotherapy (exceptions allowed for recurrent/progressive disease at discretion of primary investigator) surgery: * recovered from prior surgery other: * no other concurrent investigational agents * concurrent anticonvulsant therapy allowed

Keywords: recurrent adult brain tumor adult anaplastic astrocytoma adult anaplastic oligodendroglioma
southampton mealtime assistance study

Conditions: Malnutrition

Summary: the primary objective of the study is to determine if the use of volunteers employed specifically to focus on mealtime assistance can increase food and nutrient intake of patients admitted to an acute care of the elderly ward. the sustainability of providing helpers to increase dietary intake over a year will be assessed and linked to actual dietary intake. the secondary objectives are to assess the association between dietary intake resulting from mealtime assistance and patient satisfaction, malnutrition risk, body composition, grip strength, length of hospital stay and hospital mortality.

poor nutritional status in older people acutely admitted to hospital is common with the risk of malnutrition estimated to be greater than 40%. malnutrition is associated with major adverse clinical outcomes such as increased mortality, morbidity and length of stay at enormous cost to individuals and the health service. there is growing recognition that malnutrition is often unrecognised and untreated, and that many patients are discharged from hospital in a more malnourished state than when they were admitted. it is not surprising that complaints about nutrition and food services are amongst the commonest complaints in nhs hospitals. the standard of mealtime care in uk hospitals has been an issue of concern for a number of years. a report last year from the healthcare commission found that one in five patients who wanted help eating did not get it. a secondary analysis of data provided by the health care commission suggests that in some hospitals two out of five patients who wanted help with eating did not get it. consistent with this, the recent hungry to be heard report found that nine out of ten nurses indicated they did not always have time to help ensure patients ate properly. they also suggested that some patients were not given appropriate assistance to eat. this problem is not unique to the uk and has been reported in other countries such as australia and the usa. the aim of the present study is to investigate if the use of volunteers employed specifically to focus on mealtime assistance in a care of the elderly ward can increase food and nutrient intake, impact on body composition and improve clinical outcomes. the findings will inform service development in the nutritional care of older people across the trust and wider.

Eligibility criteria:
inclusion criteria: patients will be recruited in a consecutive prospective manner. * emergency admissions to acute medical wards and * ability to gain consent from patient or relatives exclusion criteria: * patient acutely unwell or palliative care * patient lacking capacity to consent and no assent given by relatives * patients who are tube fed or nil-by-mouth

Keywords: nutrition older hospital volunteer
camrelizumab utilization on patients with advanced liver cancer

Conditions: Advanced Hepatocellular Carcinoma

Summary: to observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer

camrelizumab ， a humanized monoclonal antibody against pd-1, has been shown to block the binding of pd-1 to pd-l1, thereby inhibiting the immune escape of tumor cells. it has a high affinity for pd-1 (kd = 3.31 nmol/l), a high acceptor proportion (85% at 200 mg) of circulating t lymphocytes, and binds to epitopes different from nivolumab and pembrolizumab，phase 1 clinical trials have shown that camrelizumab is well tolerated and has antitumor activity in patients with advanced solid tumors.camrelizumab has been approved for indication for advanced hepatocellular carcinoma the main objective of this study was to observe and evaluate the safety and efficacy of treatment regiments containing camrelizumab in advanced liver cancer。 the subjects included people over 18 years old， for men and women with advanced liver cancer confirmed by histopathology or cytology;

Eligibility criteria:
inclusion criteria: * 18 years old or more; * for both men and women; * patients with advanced liver cancer confirmed by histopathology or cytology; .volunteer to join the study, sign the informed consent, good compliance, and cooperate with the follow-up. exclusion criteria: * a known allergy to the study drug or any of its excipients; or had a severe allergic reaction to other monoclonal antibodies; * patients who are ready for or have previously received an organ or allogeneic bone marrow transplant; * pregnant or lactating women; * according to the judgment of the researcher, the patients should not be included in this study

Keywords: rws advanced liver cancer pd-1
toga study - a study of herceptin (trastuzumab) in combination with chemotherapy compared with chemotherapy alone in patients with her2-positive advanced gastric cancer

Conditions: Gastric Cancer

Summary: this parallel, randomized, open-label, multi-centre study will evaluate the effect on overall survival of trastuzumab (herceptin) in combination with a chemotherapy compared to the chemotherapy alone in patients with her2-positive advanced gastric cancer. trastuzumab (herceptin) will be administered as intravenous infusion of 6 mg/kg (loading dose 8 mg/kg) every 3 weeks. the chemotherapy consists of a combination of 6 cycles of fluorouracil (800 mg/m2/day intravenous infusion every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks), or capecitabine (xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks). treatment with trastuzumab (herceptin) will continue until disease progression. the target sample size is 300-600 patients.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age * inoperable locally advanced, recurrent, and/or metastatic cancer of the stomach or gastro-esophageal junction * adenocarcinoma * her2-positive tumors exclusion criteria: * previous chemotherapy for advanced/metastatic disease * lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome * history of cardiac disease * dyspnoea at rest, due to complications of advanced malignancy or other disease, or patients who require supportive oxygen therapy
immunosuppressive regimen on changes in renal function and transplant rejection rate in patients with lung transplant

Conditions: Lung Transplant; Complications; Chronic Kidney Diseases

Summary: this retrospective single-center analyzes the impact of switch of immunosuppressive regimen on renal function and transplant rejection rate in patients with lung transplant.

lung transplantation (ltx) is the preferred treatment modality for patients with end-stage lung disease. however, despite significant advances in treatment after ltx, comorbidities and medical complications contribute to a major extend to the high morbidity and mortality rate. chronic kidney disease is common in patients after lung transplantation, and a large proportion of these patients ultimately progress to end-stage renal disease requiring dialysis. chronic calcineurin inhibitor nephrotoxicity is one of the major risk factors for the development of chronic kidney disease. mammalian target of rapamycin (mtor) inhibitors such as everolimus have been increasingly used in combination with calcineurin inhibitors to reduce nephrotoxicity. however, whether a mtor inhibitor based immunosuppressive regime leads to lower chronic nephrotoxicity remains unknown. the aim of this study is to evaluate whether the switch of the standard immunosuppressive regime after ltx with mycophenolate/tacrolimus/prednisolon to everolimus/tacrolimus/prednisolon is associated with an improved long-term preservation of renal function without increase in rejection rate.

Eligibility criteria:
inclusion criteria: * all patients who underwent lung transplantation at the university hospital giessen and marburg, campus giessen and kerckhoff clinic bad nauheim exclusion criteria: * patients who died within 3 months after lung transplantation
a study to evaluate tocilizumab treatment in a real-life setting

Conditions: Rheumatoid Arthritis

Summary: this observational, multi-center study will evaluate the treatment regimen, treatment responses and safety of tocilizumab therapy in a routine clinical practice in participants with moderate to severe rheumatoid arthritis (ra). data will be collected for 6 months with a maximum study duration of 18 months.


Eligibility criteria:
inclusion criteria: * diagnosis of moderate to severe ra according to revised american college of rheumatology criteria * participants have started tocilizumab treatment according to routine clinical practice within 3 months prior to site opening and still in treatment, as well as participants who began treatment at enrollment exclusion criteria: * participants who have started tocilizumab treatment more than 3 months prior to site opening * participants who have previously received tocilizumab in a clinical trial setting or for compassionate use * participants who have been enrolled in an ongoing clinical trial and/or have received treatment with any investigational drug within 4 weeks prior to study start * participants with a history of autoimmune disease or joint inflammatory disease other than ra
cmr findings in covid-19 patients presenting with myocardial infarction

Conditions: Myocardial Infarction

Summary: to compare myocardial injury in covid 19 patients presented with myocardial infarction and non covid patients presented with myocardial infarction evaluated with cmr

coronavirus disease 2019 (covid-19) is a global pandemic affecting 185 countries and \>3 000 000 patients worldwide as of april 28, 2020. covid-19 is caused by severe acute respiratory syndrome coronavirus 2,. among patients with covid-19, there is a high prevalence of cardiovascular disease, and \>7% of patients experience myocardial injury from the infection (22% of critically ill patients). although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. however, much like any other respiratory tract infection, pre-existing cardiovascular disease (cvd) and cv risk factors enhance vulnerability to covid-19. further, covid-19 can worsen underly- ing cvd and even precipitate de novo cardiac complications. preliminary reports suggest that haemostatic abnormalities, including disseminated intravascular coagulation (dic), occur in patients affected by covid-19. additionally, the severe inflammatory response, critical illness, and underlying traditional risk factors may all predispose to thrombotic events, similar to prior virulent zoonotic coronavirus outbreaks cmr is the reference non-invasive standard for cardiac function and tissue characterization and may offer an effective and efficient diagnostic imaging choice to obtain critical information for clinical decision-making.

Eligibility criteria:
inclusion criteria: 1. patients presenting with symptoms and ecg indicative of acute mi (both stemi \& nstemi) and confirmed covid-19. 2. patients admitted with acute mi (both stemi \& nstemi) who develop covid-19 symptoms during hospital admission \& are confirmed by rt-pcr to have covid-19 exclusion criteria: 1. history of previous diagnosis of stemi or myocarditis. 2. history of previous pci in infarcted related artery or nstemi 3. severe respiratory distress that precludes lying supine in the cmr scanner. 4. acute kidney injury with rapidly declining gfr or gfr that is persistently below 30 ml/min/1.73 m2 (contraindication for gadopentetate dimeglumine contrast).
the pelvic floor muscle function in chinese primipara, a one-year cohort study

Conditions: Pelvic Floor Muscle Weakness; Postpartum; Primiparity

Summary: it is a prospective cohort study.the primiparas in six geographic regions of china are recruited to observe the natural recovery of pelvic floor muscle. the pelvic floor muscle function is evaluated at 6 weeks,3 months and 12 months after delivery.

the primiparas in six geographic regions of china are recruited to observe the natural recovery of pelvic floor muscle.evaluation of pelvic floor function is performed at 6 weeks, 3 months, 12 months after delivery. the modified oxford grading scale and levator ani testing are used to quantify pfm strength through vaginal palpation. pelvic floor muscles strength, endurance, repetition,vaginal contraction pressure and the knack test are evaluated using a neuromuscular stimulation therapy system of phenix (company: vivaltis -electronic concept lignon innovation, montpellier, france).

Eligibility criteria:
inclusion criteria: 1. women who give birth for the first time （including vaginal delivery and cesarean section） 2. term birth（37-42 weeks） 3. single birth 4. aged from 18 to 50 5. plan to live locally for extended periods of time exclusion criteria: 1. a history of incontinence before pregnancy 2. a history of fecal incontinence before pregnancy 3. pelvic organ prolapse before pregnancy （prolapse out of the hymen ） 4. a history of abortion or induced labour over 16 weeks of pregnancy 5. multiple pregnancy 6. the weight of the newborn is less than 2500g or more than 4000g 7. precipitate labour 8. operative vaginal delivery（obstetric forceps or vacuum extraction） 9. laceration of perineum at least level iii 10. request for pelvic floor rehabilitation exercise（patients who have entered the group can not train the pelvic floor muscle） 11. obesity （bmi before pregnancy over 25, bmi=weight (kg) / height square (m2) ） 12. asthma 13. long-term abdominal pressure（chronic cough for more than 1 months ，long-term constipation ect.） 14. diabetes 15. cotugno's disease 16. a history of pelvic floor surgery in the previous years

Keywords: pelvic floor muscle strength pelvic floor dysfunction postpartum primipara
long term and permanent contraceptive

Conditions: Contraceptive Behavior

Summary: we will study with the different variables that affect the intention to use long- acting and permanent contraceptive methods among married women in jordan through a cross sectional study. self- administered questionnaire will be distributed to aid in data collection.

in this cross-sectional study, self-administered pre-made questionnaires. (https://docs.google.com/forms/d/e/1faipqlsdjuuqynixu0aamibkhg0-iyzgtw0m5847jax0ozrnl7v7v1w/viewform ) will be distributed to married women. (women of childbearing age). the candidates will be selected according to their age (15-49), marital status (married), and pregnancy status (non-pregnant). the data collected through the questionnaires will then be processed and interpreted in order to understand the variables that affect the use of lacm and permanent contraception methods among jordanian women.

Eligibility criteria:
inclusion criteria: * females used or currently using long-term contraception exclusion criteria: * never users of contraception
a study to evaluate the effect of heat application on the delivery profile of corplex™ donepezil transdermal delivery system (tds)

Conditions: Alzheimer's Disease

Summary: a study to assess the effect of heat application on the delivery profile of corplex™ donepezil transdermal delivery system (tds)

2-way crossover study approximately 24 healthy, adult male and female subjects will be enrolled. subjects will be randomized to 1 of 2 treatment sequences prior to the first tds application in treatment period 1. for each treatment period, subjects will have one 7-day tds applied on their back. depending on which sequence a subject is randomized to, the healthy subject will either be exposed to heat or not during the tds wear time. blood samples for donepezil pk will be collected pre-dose until the end of each treatment period. adhesion will be monitored throughout the tds wear time, and skin irritation will be monitored after tds removal. subjects who complete the 2-way crossover study may be eligible to participate in the optional study extension period. in the study extension period, subjects will have their skin surface temperature monitored under the patch and adjacent to the tds. blood samples for donepezil pk will not be collected, and adhesion will not be monitored for the study extension tds wear period. safety will be monitored throughout the study by adverse event reporting and repeated clinical and laboratory evaluations.

Eligibility criteria:
inclusion criteria: * healthy, adult, male or female ≥ 30 years of age exclusion criteria: * history of any illness that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the subject by participation in the study * history or presence of alcoholism or drug abuse within the past 2 years prior to the first study product treatment * history or presence of hypersensitivity or idiosyncratic reaction to the study products or related compounds * history of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs * history or presence of excessive sweating * history or presence of hairy skin on application sites * history or presence of significant skin damage or disease at application sites * any medical or surgical procedure or trauma within 28 days prior to the first study product treatment